Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Valsartan

Valsartan

Angiotensin receptor blocker (ARB)

AdultARBHTNHFPost-MI

Indication

HTN β€’ HFrEF context β€’ post-MI context

At a glance

INDICATIONS (CORE USE)

HTN, HFrEF pathways, and post-MI contexts per protocol.

ADULT DOSE (STANDARD)

PO START 40–80 mg daily or BID (indication-dependent), titrate with labs.

MAX DOSE

Common max 320 mg/day (indication-dependent).

Route

PO once- or twice-daily depending indication

PEDIATRIC DOSE

Specialist only.

Do not miss

Must-not-miss safety points

Major warning

- Pregnancy contraindicated β†’ DO NOT use - Avoid routine dual RAAS blockade

Indications

USE IF: HTN, HFrEF/post-MI ARB-based pathways. AVOID IF: pregnancy, bilateral renal artery stenosis, baseline hyperkalemia, or active hypoperfusion.

Primary

  • Hypertension
  • HFrEF (protocol/guideline context)

Secondary

  • Post-MI LV dysfunction pathways

Dosing

STANDARD (ADULT PO)

Titrate to indication-specific targets with interval lab checks.

ADULT DOSE

Common start 40–80 mg daily/BID; titrate by BP and renal/electrolyte safety.

PEDIATRIC DOSE

N/A

MAX DOSE

Common max 320 mg/day.

Practical Note

Document whether patient is on standalone valsartan or ARNI regimen to avoid regimen errors.

Warnings

Clinical warnings

  • Lower cough/angioedema risk vs ACE inhibitors, but not zero
  • First-dose hypotension risk (especially HF / volume depletion)
  • Renal perfusion-dependent β†’ creatinine rise possible

Contraindications

  • Pregnancy
  • Bilateral renal artery stenosis (known/suspected)
  • Baseline K+ β‰₯5.5 mmol/L

Drug interactions

  • ACE inhibitor / aliskiren combination: avoid routine dual RAAS blockade (AKI, hyperkalemia, hypotension risk)
  • Potassium-sparing agents / supplements: hyperkalemia risk
  • NSAIDs β†’ ↑ AKI risk + ↓ ARB effect β€” avoid or monitor closely
  • Concurrent ACEi/aliskiren increases renal/hyperkalemia risk without routine benefit.

Special populations

Pediatrics

Specialist only.

Pregnancy

Pregnancy: contraindicated.

Lactation

specialist decision.

Renal impairment

Closely monitor creatinine/potassium with each dose increase.

Hepatic impairment

Lower starts may be needed in hepatic impairment.

Elderly

Start low and reassess falls/orthostasis risk.

Administration

PO with consistent schedule; ensure indication-specific dosing intent is clear.

Monitoring

  • Recheck: - Check creatinine + potassium within 1–2 weeks after initiation - Recheck creatinine + potassium within 1–2 weeks after dose increase - Check earlier if CKD, elderly, volume depletion, or interacting drugs
  • Hold if:
    - HOLD if:
    - SBP <90–100
    - K+ β‰₯5.5 mmol/L
    - creatinine rise >30% from baseline
    - symptomatic hypotension
  • If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

A) Mild β†’ dizziness, hypotension, fatigue B) Moderate β†’ persistent hypotension, AKI trend, hyperkalemia C) Severe β†’ refractory shock, severe hyperkalemia, respiratory compromise

Immediate Actions

β€’ Airway + continuous monitoring (ABC, BP, telemetry) β€’ Hypotension β†’ IV fluids first-line β€’ Refractory hypotension β†’ early vasopressors β€’ Stop ARB immediately

Antidote

- No specific antidote - Supportive care + hemodynamic stabilization - Hyperkalemia treatment β†’ calcium + insulin/dextrose + potassium-shifting protocol

Decontamination

β€’ Recent oral ingestion β†’ activated charcoal if protected airway and early presentation (toxicology-guided)

Escalation

- Refractory hypotension β†’ ICU / vasopressors - Severe hyperkalemia / AKI β†’ nephrology + renal replacement planning if indicated

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Valsartan is a RAAS backbone drug in multiple cardiovascular pathways when selected appropriately.

Clinical pearls

Do not confuse valsartan monotherapy with sacubitril/valsartan (ARNI) regimens. ARNI requires ACEi washout β†’ not interchangeable with ARB alone.

ARB safety

    Pharmacokinetics

    Flexible once-/twice-daily use by indication and tolerance.

    Mechanism of action

    AT1 blockade lowers vasoconstrictive and aldosterone-mediated effects.

    Common brand names

    Saudi Arabia

    Diovan, Valsartan

    Global

    (placeholder β€” verify local formulation)

    Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

    Country practice notes

    Global data (no country-specific data available)

    • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
    • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

    References

    Saudi Arabia

    • SFDA (Saudi Food & Drug Authority)
    • Saudi National Formulary / MOH (where available)

    International

    • WHO Model List of Essential Medicines (verify current edition)
    • US FDA or EU EMA product information (when national SmPC is unavailable)
    • ACC / AHA HF, HTN, CKD guidance
    • KDIGO CKD / albuminuria guidance
    • FDA / SFDA product labeling

    Do not miss

    • Pregnancy contraindicated β†’ DO NOT use
    • Hyperkalemia risk β†’ monitor potassium early
    • Creatinine rise / AKI risk (bilateral renal artery stenosis / volume depletion)
    • First-dose hypotension β†’ correct volume before starting